Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J Chairman Weldon's Salary Cut To $1 Million After Stepping Down As CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
05/07/2012 | 11:51pm CEST
   By Peter Loftus 

Johnson & Johnson (JNJ) Chairman William Weldon's annual base salary was reduced by nearly half to $1 million after he stepped down as chief executive last month, the company said Monday.

Weldon's previous annual base salary was set at $1.97 million for 2012, for his roles as both chairman and CEO, but with the expectation that J&J's board would consider the appropriate compensation for Weldon in his role as chairman only.

The decrease reflects that Weldon is no longer CEO, said spokesman Al Wasilewski.

On April 26, Alex Gorsky succeeded Weldon as CEO. Weldon is continuing as chairman and will remain an employee of the company, J&J said in a quarterly report filed with the Securities and Exchange Commission Monday.

J&J said in a previous SEC filing that in his role as chairman, Weldon will work closely with Gorsky to ensure a seamless leadership transition. During this time, all day-to-day management and operational responsibilities are being transferred to Gorsky.

Weldon will remain an employee but not a member of the J&J executive committee, which is the principal management group responsible for strategic operations and allocations of the resources of the company.

Weldon's main duties as chairman will include working with the board of directors, facilitating communication between the board and management, assisting Gorsky in business planning and strategy, representing the company before governmental and other organizations, and serving as chairman of the board's finance committee.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
02:32p JOHNSON & JOHNSON : Human Performance Institute Launches Corporate Athlete® Resi..
02:22p ACTELION : Publication of the provisional notice of the end result of Actelion t..
11:06a JOHNSON & JOHNSON : enters `Active Kids` personal care space
04/24 J&J, Takeda among interested in Brazil's Hypermarcas, sources say
04/24 JOHNSON & JOHNSON : to Host Pharmaceutical Business Review
04/24 JOHNSON & JOHNSON : Reports 2017 First-Quarter Results
04/22 JOHNSON & JOHNSON : Sun Sentinel Ira Winderman column
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 The DOs and the DON’Ts of a media pitch
04/20 JOHNSON & JOHNSON : DePuy Synthes Acquires Tissue Regeneration System’s 3D..
More news
Sector news : Pharmaceuticals - NEC
06:13pDJNasdaq Composite Tops 6000 for First Time
02:59pDJASTRAZENECA : Lung Cancer Treatment Approved in EU
02:14pDJELI LILLY AND : Working to Cut Costs
10:17a Fresenius picks up M&A pace with Akorn, Merck KGaA deals
09:09aDJNOVARTIS : Profit Dented by Investment in New Drugs -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09:35a Danish Biotech Genmab Designed Johnson & Johnson's Fastest-Growing Drug
08:00a RETIREMENT STRATEGY : Has This Bank Become Perfect For Your Retirement Portfolio..
04/24 This Earnings Season Stinks - Or Does It?
04/24 My 83 Stock Portfolio Review Highlighting Defensive Sectors And My Energy Sto..
Financials ($)
Sales 2017 75 714 M
EBIT 2017 23 391 M
Net income 2017 17 887 M
Debt 2017 6 597 M
Yield 2017 2,74%
P/E ratio 2017 18,74
P/E ratio 2018 16,83
EV / Sales 2017 4,49x
EV / Sales 2018 4,31x
Capitalization 333 142 M
More Financials
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 129 $
Spread / Average Target 4,7%
Consensus details
EPS Revisions
More Estimates Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON6.67%333 142
ROCHE HOLDING LTD.8.21%220 797
PFIZER INC.3.88%200 926
NOVARTIS AG-1.08%195 490
MERCK & CO., INC.5.55%170 359
SANOFI10.33%119 103
More Results